Aclaris Therapeutics Q2 2024 GAAP EPS $(0.15) Beats $(0.20) Estimate, Sales $2.766M Beat $1.818M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics reported its Q2 2024 financial results, with a GAAP EPS of $(0.15), beating the estimate of $(0.20). The company's sales were $2.766 million, surpassing the expected $1.818 million.
August 07, 2024 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclaris Therapeutics reported better-than-expected Q2 2024 financial results, with a GAAP EPS of $(0.15) beating the $(0.20) estimate and sales of $2.766 million surpassing the $1.818 million estimate.
The better-than-expected earnings and sales figures are likely to positively impact Aclaris Therapeutics' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100